At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
AZD9668 +1 moredrug
Likely dose
AZD9668 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Tolerability and Pharmacokinetics of Orally Administered AZD9668 in Patients With COPD
In Brief
A Phase 2 clinical trial evaluating AZD9668 and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2008
Primary CompletionSep 2008
TodayJul 2026
First PostedJun 23, 2008
Enrollment StartJun 1, 2008
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.0 years ago
Interventions
AZD9668drug
30mg oral tablets twice daily (bid) for 14 days
Placebodrug
Matched placebo to 30mg oral tablet twice daily (bid) for 14 days